Comment
doi: 10.1016/j.jtho.2020.03.020.
Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
Affiliations
- PMID: 32593453
- DOI: 10.1016/j.jtho.2020.03.020
Item in Clipboard
Comment
Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
J Thorac Oncol.
2020 Jul.
Free article
No abstract available
Comment in
-
Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".J Thorac Oncol. 2020 Jul;15(7):e127-e128. doi: 10.1016/j.jtho.2020.04.010. J Thorac Oncol. 2020. PMID: 32593454 No abstract available.
Comment on
-
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. J Thorac Oncol. 2020. PMID: 31988000 Free PMC article.
Similar articles
-
Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".J Thorac Oncol. 2020 Jul;15(7):e127-e128. doi: 10.1016/j.jtho.2020.04.010. J Thorac Oncol. 2020. PMID: 32593454 No abstract available.
-
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.J Thorac Oncol. 2021 Jul;16(7):e51-e54. doi: 10.1016/j.jtho.2021.03.006. J Thorac Oncol. 2021. PMID: 34154791 No abstract available.
-
[The progress of KIF5B-RET fusion gene in non-small cell lung cancer].Zhonghua Jie He He Hu Xi Za Zhi. 2013 Jul;36(7):524-6. Zhonghua Jie He He Hu Xi Za Zhi. 2013. PMID: 24262090 Review. Chinese. No abstract available.
-
KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.Cancer. 2013 Apr 15;119(8):1486-94. doi: 10.1002/cncr.27940. Epub 2013 Feb 1. Cancer. 2013. PMID: 23378251
-
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.Expert Rev Anticancer Ther. 2022 Aug;22(8):785-794. doi: 10.1080/14737140.2022.2093190. Epub 2022 Jun 27. Expert Rev Anticancer Ther. 2022. PMID: 35726802 Review.
Cited by
-
Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report.Front Oncol. 2023 Oct 9;13:1264231. doi: 10.3389/fonc.2023.1264231. eCollection 2023. Front Oncol. 2023. PMID: 37876974 Free PMC article.
-
Update on Molecular Diagnostics in Thyroid Pathology: A Review.Genes (Basel). 2023 Jun 22;14(7):1314. doi: 10.3390/genes14071314. Genes (Basel). 2023. PMID: 37510219 Free PMC article. Review.
-
Progress and challenges in RET-targeted cancer therapy.Front Med. 2023 Apr;17(2):207-219. doi: 10.1007/s11684-023-0985-y. Epub 2023 May 3. Front Med. 2023. PMID: 37131086 Review.
-
Molecular features of aggressive thyroid cancer.Front Oncol. 2022 Dec 20;12:1099280. doi: 10.3389/fonc.2022.1099280. eCollection 2022. Front Oncol. 2022. PMID: 36605433 Free PMC article. Review.
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
